Multiple Sclerosis. Demyelinating disease of central nervous system, unspecified
Conditions
Interventions
Intervention 1: Intervention group: The intervention group consisted of 26 patients who will be treated with Atomoxetine capsules at a dose of 40 mg daily for 2 weeks and then increased to 80 mg daily
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Multiple Sclerosis based on McDonald's criteria Age between 18 to 55 years Testable Measurable Cognitive impairment (MACFIMS) attributed to Multiple Sclerosis
Exclusion criteria
Exclusion criteria: Continued use of Stimulant Clinical relapse of Multiple Sclerosis with in 60 days of screening Changes in the treatment of Multiple Sclerosis within 90 days of screening Existence of any underlying factor and disease that causes dementia and cognitive impairment Proof of moderate to severe depression with a Beck's test Contraindications to the use of Atomoxetine Confirmation of cognitive impairment related to Multiple Sclerosis with McFimes test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive Disorder Score in MacFims Questionnaire. Timepoint: Perform MacFims test at the beginning of the study and three months after the start of the study. Method of measurement: MacFims Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Accompanying depression score. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Beck Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEffat Amouzadeh
Ahvaz University of Medical Sciences
Outcome results
None listed